# A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma

> **NCT02316106** · PHASE2 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 123 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** daratumumab
- **DRUG:** daratumumab
- **DRUG:** daratumumab

## Key facts

- **NCT ID:** NCT02316106
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-20
- **Primary completion:** 2023-06-02
- **Final completion:** 2024-06-03
- **Target enrollment:** 123 (ACTUAL)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02316106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02316106, "A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02316106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*